Clinical Trial

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-16; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-06-13
Trial Details
NCT Number NCT06940830
Lead Sponsor Swedish Orphan Biovitrum
Collaborators: PSI CRO
Conditions Hemophilia A
Enrollment 250 participants
Start Date 2025-05-21
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-30